FY 2020 Results & 2021 Outlook
Investor Presentation - February 24th, 2021
P I O N E E R I N G D I A G N O S T I C S
DISCLAIMER
This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMérieux. Further information regarding these assumptions, risks and estimates are described in the documents registered with the Autorité des Marchés Financiers.
The forward-looking statements contained in this presentation apply only up to the date of the presentation. Accordingly, the Company cannot give any assurance as to whether it will achieve the objectives described in this presentation, and makes no commitment or undertaking to update or otherwise revise such information.
This document does not constitute an offer to sell or an invitation or solicitation of an offer to subscribe for or purchase any securities, and this shall not form the basis for or be used for any such offer or invitation or other contract or engagement in any jurisdiction.
2
AGENDA
OVERVIEW OF bioMérieux
FY 2020 ACTIVITY REVIEW
FY 2020 FINANCIAL RESULTS
CSR AMBITION
2021 OUTLOOK
KEY TAKEAWAYS - 2020 PERFORMANCE
SALES
€3,118m
+19.7%
at constant exchange rates and scope of consolidation
FREE CASH FLOW
€328m
4
PROFITABILITY
€613m
19.6%of sales vs. 14.5% in 2019
LEVERAGE
0.1x EBITDA
BUSINESS TRENDS
Molecular biology
Microbiology
Immunoassays
Industry
COMPREHENSIVE COVID-19
IN VITRO DIAGNOSTIC SOLUTION
EXTRACTION | PCR TEST | SYNDROMIC | SEROLOGY |
ARGENE®
SARS-CoV-2R-GENE® | VIDAS® | ||
EMAG® & | SARS-Cov-2 RESPI R-GENE® | BIOFIRE® RP2.1 | |
anti-SARS-CoV-2 IgM | |||
EASYMAG® | BIOFIRE® RP2.1plus | anti-SARS-CoV-2 IgG | |
High quality and fully | Ready-to-use kits with internal | Rapid, easy, automated syndromic | Fully automated qualitative assays |
automated RNA extraction | controls allowing mid-to-high | testing of 22 or 23 pathogens | for the detection of antibodies |
prior to amplification | size batch analyses on most | that cause respiratory infections, | in patients who have been exposed |
and detection | real-time PCR systems. The | including SARS-CoV-2 | to SARS-CoV-2 |
5
Single plex SARS-CoV-2R-GENE® may be used on saliva and oropharyngeal (throat) swab specimens
Pour lire la suite de ce noodl, vous pouvez consulter la version originale ici.
Attachments
- Original document
- Permalink
Disclaimer
BioMérieux SA published this content on 16 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 April 2021 09:35:05 UTC.